# A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

> **NCT03918447** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 667 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney
- ADPKD

## Interventions

- **DRUG:** Bardoxolone methyl oral capsule
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03918447
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-29
- **Primary completion:** 2023-08-08
- **Final completion:** 2023-08-08
- **Target enrollment:** 667 (ACTUAL)
- **Why stopped:** Discontinuation of all bardoxolone chronic kidney disease programs
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03918447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03918447, "A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03918447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*